Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

FTSE 100 broadly flat amid decline in services sector activity, BoE in focus

Published 03/02/2021, 12:09
Updated 03/02/2021, 12:13
© Reuters.

By Samuel Indyk

Investing.com – The FTSE 100 trades relatively flat at the midpoint of the trading day despite services sector activity falling to its lowest level since May. The IHS Markit services PMI survey showed that businesses were struggling in the latest lockdown, particularly those in the hospitality and travel & leisure sector. However, businesses are optimistic with growth expectations at their highest level since 2014 on prospects of a strong reopening as the vaccine effort continues.

Vodafone Group PLC (LON:VOD) shares rose to the top of the blue-chip index after a positive trading update where they had benefited from work from home policies in Germany. Separately, they announced that the spinoff of their towers division, Vantage Towers, was on track for early 2021. Reuters had earlier reported that the company is expected to list the division in Frankfurt in March this year.

Vaccine Makers

AstraZeneca PLC (LON:AZN) was again in focus after early studies showed that a single dose of the vaccine was 76% effective for up to 12 weeks, justifying the UK’s decision to vaccinate as many people as possible in as quick a time frame as feasible. The data - published by Oxford University - is not yet peer-reviewed but will provide the UK government with assurance that they have made the right decision. On the other hand, France has followed Germany’s lead and recommended that the Oxford/AstraZeneca jab not be given to those over 65, given a lack of data in the early trials. This comes despite the European Medicines Agency authorising the use of the jab for over 65s.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Another UK-based pharmaceutical company, GlaxoSmithKline PLC (LON:GSK), announced a deal with Germany’s CureVac NV (NASDAQ:CVAC) to work together to develop vaccines against the new variants of the virus. The deal, worth EUR 150mln, will also see GlaxoSmithKline assist in manufacturing CureVac’s current vaccine candidate for the original strain.

Sterling

The pound fell against the US dollar and was broadly flat against the Euro as markets look ahead to tomorrow’s Bank of England interest rate decision. Focus will be on whether the central bank sees negative rates as part of their toolkit should economic prospects weaken further. Trading ranges have been relatively narrow with GBP/USD between 1.3624-1.3665 and EUR/GBP between 0.8801-0.8823.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.